Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Next Previous
X
Search
Trial Profile

Phase Ib study of limited androgen ablation and two dose levels of temsirolimus (NSC 683864) in patients with prostate cancer who have a biochemical relapse after prostatectomy and/or radiotherapy

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temsirolimus (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin; Nilutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker

    • Most Recent Events

    • 02 Jul 2010 Planned end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov
    • 01 Feb 2008 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top